Regeneron Pharmaceuticals (REGN) Lowered to Neutral at Citigroup

Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by equities research analysts at Citigroup from a “buy” rating to a “neutral” rating in a note issued to investors on Friday, MarketBeat.com reports. They currently have a $380.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $480.00. Citigroup’s price objective points to a potential upside of 1.75% from the stock’s previous close.

Several other equities research analysts also recently weighed in on REGN. J P Morgan Chase & Co reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Thursday, August 3rd. Canaccord Genuity set a $522.00 target price on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 3rd. BMO Capital Markets set a $491.00 target price on shares of Regeneron Pharmaceuticals and gave the company a “hold” rating in a research note on Thursday, August 3rd. UBS reissued a “buy” rating and issued a $535.00 target price (up previously from $489.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 4th. Finally, Robert W. Baird downgraded shares of Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $408.00 target price on the stock. in a research note on Tuesday, August 8th. Two analysts have rated the stock with a sell rating, sixteen have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Regeneron Pharmaceuticals has a consensus rating of “Hold” and an average price target of $467.84.

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded up $11.61 on Friday, hitting $373.47. 1,819,523 shares of the stock traded hands, compared to its average volume of 912,162. Regeneron Pharmaceuticals has a 1-year low of $340.09 and a 1-year high of $543.55. The stock has a market capitalization of $40,130.00, a P/E ratio of 31.69, a P/E/G ratio of 1.44 and a beta of 1.56. The company has a current ratio of 3.63, a quick ratio of 3.07 and a debt-to-equity ratio of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The business had revenue of $1.50 billion for the quarter, compared to the consensus estimate of $1.45 billion. During the same quarter in the prior year, the firm posted $3.13 earnings per share. The business’s revenue for the quarter was up 23.0% on a year-over-year basis. sell-side analysts forecast that Regeneron Pharmaceuticals will post 13.55 EPS for the current year.

In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,500 shares of the stock in a transaction dated Thursday, October 5th. The shares were sold at an average price of $475.00, for a total transaction of $712,500.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Charles A. Baker sold 2,000 shares of the stock in a transaction dated Friday, September 29th. The stock was sold at an average price of $450.00, for a total transaction of $900,000.00. Following the transaction, the director now owns 11,000 shares in the company, valued at $4,950,000. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 4,352 shares of company stock worth $2,037,772. Company insiders own 10.80% of the company’s stock.

A number of institutional investors have recently modified their holdings of the business. Sequoia Financial Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 1.7% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 712 shares of the biopharmaceutical company’s stock worth $350,000 after acquiring an additional 12 shares in the last quarter. Capital Planning Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 2.1% during the 2nd quarter. Capital Planning Advisors LLC now owns 582 shares of the biopharmaceutical company’s stock worth $286,000 after acquiring an additional 12 shares in the last quarter. Princeton Capital Management Inc. grew its holdings in Regeneron Pharmaceuticals by 0.6% during the 2nd quarter. Princeton Capital Management Inc. now owns 2,511 shares of the biopharmaceutical company’s stock worth $1,233,000 after acquiring an additional 15 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its holdings in Regeneron Pharmaceuticals by 0.4% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 5,661 shares of the biopharmaceutical company’s stock worth $2,780,000 after acquiring an additional 20 shares in the last quarter. Finally, National Asset Management Inc. grew its holdings in Regeneron Pharmaceuticals by 3.1% during the 2nd quarter. National Asset Management Inc. now owns 856 shares of the biopharmaceutical company’s stock worth $421,000 after acquiring an additional 26 shares in the last quarter. Institutional investors own 69.47% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/12/01/regeneron-pharmaceuticals-regn-lowered-to-neutral-at-citigroup.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply